Bevacizumab for neovascular age-related macular degeneration (ABC trial): multicenter randomized double-masked study

References

• Tufail A, Patel PJ, Egan C et al.; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC trial): multicentre randomised double masked study. BMJ340, c2459 (2010).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med.355(14), 1419–1431 (2006).
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med.355(14), 1432–1444 (2006).
   PubMed Web of Science ®Google Scholar
• Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol.247(1), 1–11 (2009).
   PubMed Web of Science ®Google Scholar
• Ziemssen F, Grisanti S, Bartz-Schmidt KU, Spitzer MS. Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? Medications Aging26(4), 295–320 (2009).
   Google Scholar
• [No authors listed]. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Arch. Ophthalmol.117(10), 1329–1345 (1999).
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med.351(27), 2805–2816 (2004).
   PubMed Web of Science ®Google Scholar
• Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology113(3), 363–372 (2006).
   PubMed Web of Science ®Google Scholar
• Spaide RF, Laud K, Fine HF et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina26(4), 383–390 (2006).
   PubMed Web of Science ®Google Scholar
• Fung AE, Lalwani GA, Rosenfeld PJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am. J. Ophthalmol.143(4), 566–583 (2007).
   PubMed Web of Science ®Google Scholar
• Lalwani GA, Rosenfeld PJ, Fung AE et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am. J. Ophthalmol.148(1), 43–58 e1 (2009).
   PubMed Web of Science ®Google Scholar
• Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization – verteporfin in photodynamic therapy report 2. Am. J. Ophthalmol.131(5), 541–560 (2001).
   PubMed Web of Science ®Google Scholar
• Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess medication safety worldwide. Br. J. Ophthalmol.90(11), 1344–1349 (2006).
   PubMed Web of Science ®Google Scholar
• Michels S, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology112(6), 1035–1047 (2005).
   PubMed Web of Science ®Google Scholar
• Chong NV. Should Avastin be used to treat age-related macular degeneration in the NHS? – No. Eye (Lond.)23(6), 1250–1253 (2009).
   PubMed Web of Science ®Google Scholar
• Wong TY. Age-related macular degeneration and cardiovascular disease in the era of anti-vascular endothelial growth factor therapies. Am. J. Ophthalmol.148(3), 327–329 (2009).
   Google Scholar
• Wong TY, Klein R, Sun C et al. Age-related macular degeneration and risk for stroke. Ann. Intern. Med.145(2), 98–106 (2006).
   PubMed Web of Science ®Google Scholar
• Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology116(9), 1731–1739 (2009).
   PubMed Web of Science ®Google Scholar
• Hu CC, Ho JD, Lin HC. Neovascular age-related macular degeneration and the risk of stroke: a five year population-based follow-up study. Stroke41(4), 613–617 (2010).
   PubMed Web of Science ®Google Scholar
• Wickremasinghe SS, Michalova K, Gilhotra J et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology115(11), 1911–1915 (2008).
   PubMed Web of Science ®Google Scholar
• Peters S, Heiduschka P, Julien S et al. Tübingen Bevacizumab Study Group. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am. J. Ophthalmol.143(6), 995–1002 (2007).
   PubMed Web of Science ®Google Scholar
• Spitzer MS, Wallenfels-Thilo B, Sierra A et al. Tuebingen Bevacizumab Study Group. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br. J. Ophthalmol.90(10), 1316–1321 (2006).
   PubMed Web of Science ®Google Scholar
• Funk M, Kriechbaum K, Prager F et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest. Ophthalmol. Vis. Sci.50(3), 1025–1032 (2009).
   PubMed Web of Science ®Google Scholar
• Klettner AK, Kruse ML, Meyer T, Wesch D, Kabelitz D, Roider J. Different properties of VEGF-antagonists: bevacizumab but not ranibizumab accumulates in RPE cells. Graefes Arch. Clin. Exp. Ophthalmol.247(12), 1601–1608 (2009).
   PubMed Web of Science ®Google Scholar
• Mordenti J, Cuthbertson RA, Ferrara N et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol. Pathol.27(5), 536–544 (1999).
   PubMed Web of Science ®Google Scholar
• Mordenti J, Thomsen K, Licko V et al. Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. Toxicol. Sci.52(1), 101–106 (1999).
   PubMed Web of Science ®Google Scholar
• Saint-Geniez M, Maldonado AE, D’Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest. Ophthalmol. Vis. Sci.47(7), 3135–3142 (2006).
   PubMed Web of Science ®Google Scholar
• Nishijima K, Ng YS, Zhong L et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol.171(1), 53–67 (2007).
   PubMed Web of Science ®Google Scholar
• Subramanian ML, Ness S, Abedi G et al. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am. J. Ophthalmol.148(6), 875–882 e1 (2009).
   PubMed Web of Science ®Google Scholar